184 related articles for article (PubMed ID: 8718426)
41. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
[TBL] [Abstract][Full Text] [Related]
42. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
[TBL] [Abstract][Full Text] [Related]
43. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview.
Shepherd FA
Anticancer Drugs; 1995 Dec; 6 Suppl 6():19-25. PubMed ID: 8718421
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T
Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
47. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
[TBL] [Abstract][Full Text] [Related]
48. [Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Asai G; Fukuoka M
Gan To Kagaku Ryoho; 1999 Jun; 26(7):884-9. PubMed ID: 10396314
[TBL] [Abstract][Full Text] [Related]
49. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
[TBL] [Abstract][Full Text] [Related]
50. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
[TBL] [Abstract][Full Text] [Related]
51. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Modi S; Currie VE; Seidman AD; Bach AM; Panageas KS; Theodoulou M; Moasser MM; D'Andrea GM; Lake DE; Choi J; Norton L; Hudis CA
Clin Breast Cancer; 2005 Apr; 6(1):55-60. PubMed ID: 15899073
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Catimel G; Vermorken JB; Clavel M; de Mulder P; Judson I; Sessa C; Piccart M; Bruntsch U; Verweij J; Wanders J
Ann Oncol; 1994 Jul; 5(6):543-7. PubMed ID: 7918127
[TBL] [Abstract][Full Text] [Related]
54. Gemcitabine: safety profile unaffected by starting dose.
Martin C; Pollera CF
Int J Clin Pharmacol Res; 1996; 16(1):9-18. PubMed ID: 9001925
[TBL] [Abstract][Full Text] [Related]
55. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
[TBL] [Abstract][Full Text] [Related]
56. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
57. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
58. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
59. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
60. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]